Circulating PRCP in STEMI Patients Undergoing Primary PCI

Myocardial Infarction Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02772133
• Other study ID #: 2015GSF118133
• Status: Completed
• Start date: May 2016
• Est. completion date: July 2016

Study information

• Verified date: December 2019
• Source: Qilu Hospital of Shandong University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Purpose: The purpose of this study is to evaluate the impact of acute ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (PCI) on circulating prolylcarboxypeptidase (PRCP) level and activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 275
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation =2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes;

• Age =18 years;

• Informed consent from subject or next of kin.

Exclusion Criteria:

• Nonischaemic Cardiomyopathy;

• Cardiac surgery planed in the 6 months;

• Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation);

• Renal or hepatic failure;

• Malignancy, HIV, or central nervous system disorder;

• Cardiopulmonary resuscitation >15 min and compromised level of consciousness;

• Cardiogenic shock;

• Current participation in any research study involving investigational drugs or devices;

• No written consensus;

• Previous myocardial infarction.

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Percutaneous Coronary Intervention
• PRCP

Intervention

Procedure:
• Primary PCI

Locations

Country	Name	City	State
China	Jinan Central Hospital, Shandong University	Jinan	Shandong
China	Qianfoshan Hospital, Shandong University	Jinan	Shandong
China	Shandong Provincial Hospital, Shandong University	Jinan	Shandong
China	Shandong University Qilu Hospital	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Circulating PRCP level		1 month
Primary	Circulating PRCP activity		1 month
Secondary	Circulating Ang II level		1 month
Secondary	Circulating Ang-(1-7) level		1 month
Secondary	Circulating BK-(1-9) level		1 month
Secondary	Circulating KBK-(1-9) level		1 month